Interpretation of NCCN guidelines version 1. 2023 thymomas and thymic carcinomas
- VernacularTitle:2023年第1版《NCCN胸腺瘤和胸腺癌临床实践指南》解读
- Author:
Jiahe LI
1
,
2
;
Guangyu XIANG
1
,
2
;
Jipeng ZHANG
3
,
4
;
Chenghui JIA
3
,
4
;
Ting CHANG
4
,
5
;
Zhe RUAN
4
,
5
;
Li GONG
4
,
6
;
Qiang LU
3
,
4
Author Information
1. Basic Medical College, Air Force Military Medical University, Xi&rsquo
2. an, 710032, P. R. China
3. Department of Thoracic Surgery, Tangdu Hospital, Air Force Military Medical University, Xi&rsquo
4. an, 710038, P. R. China
5. Department of Neurology, Tangdu Hospital, Air Force Military Medical University, Xi&rsquo
6. Department of Pathology, Tangdu Hospital, Air Force Military Medical University, Xi&rsquo
- Publication Type:Journal Article
- Keywords:
Thymoma;
thymic carcinoma;
NCCN guidelines;
guideline interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(04):506-513
- CountryChina
- Language:Chinese
-
Abstract:
National Comprehensive Cancer Network (NCCN) has updated and released the latest content of NCCN guidelines version 1. 2023 thymomas and thymic carcinomas (known as "guidelines"). The guideline sets standards for the diagnosis and treatment of thymoma and thymic carcinoma based on high quality clinical evidence and the latest advances in research. There have been some updates and revisions in the latest two versions of the guidelines, mainly focusing on the principles of radiotherapy, the principles of systematic therapy, multidisciplinary participation and the improvement of some footnotes, compared with the first version of the guidelines in 2022. In this paper, the contents of the new guideline will be interpreted in order to provide reference for the work of thymoma and thymic carcinoma in our country at the present stage.
